Pharmalink: Launching into Phase III
Pharmalink AB has hired Renee Aguiar-Lucander as Chief Executive Officer. She will lead the expansion and strategic development of the Swedish specialty pharmaceutical company following the clinical success of its orphan drug Nefecon.
Prior to joining Pharmalink, Aguiar-Lucander was Partner and COO of Omega Fund Management, an international healthcare fund based in Boston. She was previously a Partner at the venture group of 3i Group plc, where she managed the European and US legacy healthcare and technology portfolios, and had responsibility for the groups public holdings. Prior to this, Aguiar-Lucander was European Group Head and Managing Director at a US based global investment bank. Aguiar-Lucander holds a BA in Finance from Stockholm School of Economics and a MBA from INSEAD.
Pharmalinks current CEO, Dr Johan Häggblad, will take on the role of COO and will continue to lead clinical and product development.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium